论文部分内容阅读
目的探讨不同剂量利拉鲁肽在2型糖尿病合并冠心病治疗中的应用价值。方法选取2013年10月—2015年10月绵阳市中医医院收治的2型糖尿病合并冠心病患者70例,随机分为对照组和治疗组,每组35例。对照组患者采用利拉鲁肽0.6mg/次治疗;治疗组患者采用利拉鲁肽1.2mg/次治疗。比较两组患者的治疗效果、血糖恢复正常时间、心电图检查结果恢复正常时间、治疗时间、不良反应发生情况。结果治疗组总有效率高于对照组,血糖水平恢复正常时间、心电图检查结果恢复正常时间、治疗时间短于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论利拉鲁肽1.2mg/次治疗2型糖尿病合并冠心病患者的治疗效果更加明显,同时不会增加不良反应。
Objective To investigate the value of different doses of liraglutide in the treatment of type 2 diabetes mellitus complicated with coronary heart disease. Methods Seventy patients with type 2 diabetes mellitus complicated with coronary heart disease admitted to Mianyang Hospital of Traditional Chinese Medicine from October 2013 to October 2015 were randomly divided into control group and treatment group with 35 cases in each group. Patients in the control group received liraglutide 0.6 mg / time; patients in the treatment group received liraglutide 1.2 mg / time. The therapeutic effect, the normal time of blood glucose recovery, the normal time of electrocardiogram examination, the treatment time and the adverse reactions were compared between the two groups. Results The total effective rate of the treatment group was higher than that of the control group, the blood glucose level returned to normal time, the electrocardiogram returned to normal time and the treatment time was shorter than that of the control group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Liraglutide 1.2mg / time treatment of type 2 diabetes patients with coronary heart disease treatment more obvious effect, without increasing adverse reactions.